Related Experiment Video

Updated: May 1, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy

Nethia Mohana-Kumaran1, David S Hill, John D Allen

  • 1The Centenary Institute, Newtown, NSW, Australia; School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.

Pigment Cell & Melanoma Research
|March 25, 2014
PubMed

Insights

Targeting apoptosis regulators like MCL-1 and IAPs with BH3- and SMAC-mimetics offers a promising strategy to overcome melanoma drug resistance. Combination therapies, especially with BRAF-inhibitors, are a key priority for future melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Melanoma drug resistance frequently arises from defects in the intrinsic apoptosis pathway.
  • Targeting apoptosis regulators is a promising strategy to enhance melanoma treatment sensitivity.

Purpose of the Study:

  • To investigate the role of apoptosis regulators (BCL-2 family, IAPs) in melanoma drug resistance.
  • To evaluate the potential of BH3- and SMAC-mimetics in overcoming this resistance.

Main Methods:

  • Utilized BH3-mimetics to study BCL-2 family signaling, focusing on MCL-1 and NOXA.
  • Employed SMAC-mimetics to investigate the role of XIAP and cIAPs in apoptosis induction.
  • Reviewed existing literature on mimetic drug efficacy in solid tumors, including melanoma.

Main Results:

  • BH3-mimetics highlight MCL-1 and NOXA as critical in BCL-2 family signaling.
  • SMAC-mimetics demonstrate the necessity of targeting both XIAP and cIAPs for effective apoptosis induction.
  • Melanoma and other solid tumors show limited sensitivity to mimetic drugs as single agents.

Conclusions:

  • BH3- and SMAC-mimetics are valuable tools for understanding and potentially overcoming melanoma apoptotic resistance.
  • Combination therapies involving these mimetics, particularly with BRAF-inhibitors, represent a high-priority research direction for melanoma treatment.
Keywords:
BH3-mimeticIAP antagonistMCL-1 antagonistSMAC-mimeticdrug resistanceintrinsic apoptosis pathwaymelanoma therapy

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

6.5K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
12.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
99